What Researchers Did
Researchers at Duke University Medical Center treated 49 patients with clostridial myonecrosis using hyperbaric oxygen (HBO) over a decade, alongside extensive experimental studies.
What They Found
Overall survival for the 49 patients treated with hyperbaric oxygen for clostridial myonecrosis was 73.5%. Survival rates varied by involvement, with 92.3% for extremity-confined cases, 53.3% for combined extremity and trunk, and 50% for primary trunk involvement. Experimental studies further indicated that HBO significantly reduced both mortality and morbidity rates.
What This Means for Canadian Patients
While this study is older, it suggests that hyperbaric oxygen therapy could be a valuable treatment option for Canadian patients diagnosed with severe clostridial myonecrosis. However, preventing this infrequent illness through strict adherence to wound care principles remains the most effective approach.
Canadian Relevance
This study has no direct Canadian connection as it was conducted at Duke University Medical Center in the United States.
Study Limitations
A key limitation is the absence of a controlled study, meaning the therapeutic efficacy of hyperbaric oxygen in treating clostridial myonecrosis is not fully proven.